101 related articles for article (PubMed ID: 32669649)
1. Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis.
Kato M; Sasaki S; Nakamura T; Kurokawa K; Yamada T; Ochi Y; Ihara H; Takahashi F; Takahashi K
Sci Rep; 2020 Jul; 10(1):12080. PubMed ID: 32669649
[TBL] [Abstract][Full Text] [Related]
2. Author Correction: Imaging and Pathological Features of Idiopathic Portal Hypertension and Differential Diagnosis from Liver Cirrhosis.
Zhao ZL; Wei Y; Wang TL; Peng LL; Li Y; Yu MA
Sci Rep; 2020 Apr; 10(1):7586. PubMed ID: 32350347
[TBL] [Abstract][Full Text] [Related]
3. Author Correction: Targeting cardiac fibrosis with engineered T cells.
Aghajanian H; Kimura T; Rurik JG; Hancock AS; Leibowitz MS; Li L; Scholler J; Monslow J; Lo A; Han W; Wang T; Bedi K; Morley MP; Saldana RAL; Bolar NA; McDaid K; Assenmacher CA; Smith CL; Wirth D; June CH; Margulies KB; Jain R; Puré E; Albelda SM; Epstein JA
Nature; 2019 Dec; 576(7785):E2. PubMed ID: 31723271
[TBL] [Abstract][Full Text] [Related]
4. Author Correction: Arginyltransferase knockdown attenuates cardiac hypertrophy and fibrosis through TAK1-JNK1/2 pathway.
Singh K; Gupta A; Sarkar A; Gupta I; Rana S; Sarkar S; Khan S
Sci Rep; 2020 Jun; 10(1):10662. PubMed ID: 32581244
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
[TBL] [Abstract][Full Text] [Related]
6. Author Correction: ENMD-1068 inhibits liver fibrosis through attenuation of TGF-β1/Smad2/3 signaling in mice.
Sun Q; Wang Y; Zhang J; Lu J
Sci Rep; 2019 Dec; 9(1):19125. PubMed ID: 31819147
[TBL] [Abstract][Full Text] [Related]
7. Author Correction: Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis.
Simonin J; Bille E; Crambert G; Noel S; Dreano E; Edwards A; Hatton A; Pranke I; Villeret B; Cottart CH; Vrel JP; Urbach V; Baatallah N; Hinzpeter A; Golec A; Touqui L; Nassif X; Galietta LJV; Planelles G; Sallenave JM; Edelman A; Sermet-Gaudelus I
Sci Rep; 2019 Nov; 9(1):17535. PubMed ID: 31754179
[TBL] [Abstract][Full Text] [Related]
8. Author Correction: Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing.
Maule G; Casini A; Montagna C; Ramalho AS; De Boeck K; Debyser Z; Carlon MS; Petris G; Cereseto A
Nat Commun; 2020 Oct; 11(1):5457. PubMed ID: 33093446
[TBL] [Abstract][Full Text] [Related]
9. Author Correction: Effects of the serine protease inhibitor rBmTI-A in an experimental mouse model of chronic allergic pulmonary inflammation.
Florencio AC; de Almeida RS; Arantes-Costa FM; Saraiva-Romanholo BM; Duran AF; Sasaki SD; Martins MA; Lopes FDTQS; Tibério IFLC; Leick EA
Sci Rep; 2019 Nov; 9(1):17011. PubMed ID: 31719669
[TBL] [Abstract][Full Text] [Related]
10. Author Correction: A possible association between fructose consumption and pulmonary emphysema.
Suehiro CL; de Toledo-Arruda AC; Vieira RP; de Almeida FM; Olivo CR; de Arruda Martins M; Lin CJ
Sci Rep; 2020 Sep; 10(1):16158. PubMed ID: 32978438
[TBL] [Abstract][Full Text] [Related]
11. Author Correction: Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity.
Alsaied T; Niss O; Tretter JT; Powell AW; Chin C; Fleck RJ; Cnota JF; Malik P; Quinn CT; Nagueh SF; Taylor MD; Mazur WM
Sci Rep; 2020 Mar; 10(1):4880. PubMed ID: 32165646
[TBL] [Abstract][Full Text] [Related]
12. Author Correction: A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis.
McWilliam SJ; Rosala-Hallas A; Jones AP; Shaw V; Greenhalf W; Jaki T; Smyth AR; Smyth RL; Pirmohamed M
Sci Rep; 2020 Mar; 10(1):4730. PubMed ID: 32152372
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Keating GM
Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
[TBL] [Abstract][Full Text] [Related]
14. Author Correction: Cellular census of human fibrosis defines functionally distinct stromal cell types and states.
Layton TB; Williams L; McCann F; Zhang M; Fritzsche M; Colin-York H; Cabrita M; Ng MTH; Feldmann M; Sansom SN; Furniss D; Xie W; Nanchahal J
Nat Commun; 2020 Jun; 11(1):3275. PubMed ID: 32581254
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
16. Author Correction: PHF14: an innate inhibitor against the progression of renal fibrosis following folic acid-induced kidney injury.
Yang B; Chen S; Wu M; Zhang L; Ruan M; Chen X; Chen Z; Mei C; Mao Z
Sci Rep; 2020 Apr; 10(1):6036. PubMed ID: 32242053
[TBL] [Abstract][Full Text] [Related]
17. Author Correction: WWP2 regulates pathological cardiac fibrosis by modulating SMAD2 signaling.
Chen H; Moreno-Moral A; Pesce F; Devapragash N; Mancini M; Heng EL; Rotival M; Srivastava PK; Harmston N; Shkura K; Rackham OJL; Yu WP; Sun XM; Tee NGZ; Tan ELS; Barton PJR; Felkin LE; Lara-Pezzi E; Angelini G; Beltrami C; Pravenec M; Schafer S; Bottolo L; Hubner N; Emanueli C; Cook SA; Petretto E
Nat Commun; 2019 Sep; 10(1):4085. PubMed ID: 31501434
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
Ogura T; Taniguchi H; Azuma A; Inoue Y; Kondoh Y; Hasegawa Y; Bando M; Abe S; Mochizuki Y; Chida K; Klüglich M; Fujimoto T; Okazaki K; Tadayasu Y; Sakamoto W; Sugiyama Y
Eur Respir J; 2015 May; 45(5):1382-92. PubMed ID: 25504994
[TBL] [Abstract][Full Text] [Related]
19. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
[TBL] [Abstract][Full Text] [Related]
20. Subgroup Analysis for Chinese Patients Included in the INPULSIS
Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
